AI Article Synopsis
- Rhabdomyolysis can lead to renal failure in up to 40% of cases and can be caused by both traumatic and nontraumatic factors.
- Colistin, an antibiotic, is effective but often causes nephrotoxicity, potentially leading to acute tubular necrosis due to cell damage.
- This report discusses a unique case of nontraumatic rhabdomyolysis linked to colistin, highlighting severe tetraparesis, which has not been previously documented in literature.
Article Abstract
Rhabdomyolysis is a clinical condition that causes renal failure up to 40%. Rhabdomyolysis may be traumatic or nontraumatic. Colistin (polymyxin E) is an effective antibiotic. Nephrotoxicity is a frequently encountered side effect. The nephrotoxic effect of colistin is thought to be associated with increased membrane permeability, cell swelling and lysis, and the development of acute tubular necrosis. Here, we report a case of nontraumatic rhabdomyolysis associated with the use of colistin. There is only one report of rhabdomyolysis secondary to colistin in the literature, and there is no report of a case developing severe tetraparesis, as in our case.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/0886022X.2012.684513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Colistin induced neurotoxicity with bulbar palsy. A case report and literature review.
IDCases
November 2024
Hospital Medicine Department, Integrated Hospital Care Institute, Cleveland Clinic Abu-Dhabi, PO BOX: 112412, Abu-Dhabi, United Arab Emirates.
Colistin, a polymyxin antibiotic, is increasingly used to manage infections caused by multidrug-resistant gram-negative bacteria. This case report documents the occurrence of colistin-induced neurotoxicity manifesting as bulbar palsy in a 38-year-old male with a complex medical history. The patient, presenting with septic shock secondary to a diabetic foot ulcer, was administered colistin and meropenem, leading to a progressive onset of neurological symptoms.
View Article and Find Full Text PDFEvaluating the Efficacy of Inhaled Colistin via Two Nebulizer Types in Ventilator-Associated Pneumonia: Prospective Randomized Trial.
Antibiotics (Basel)
November 2024
Division of Pulmonary and Critical Care Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 33342, Taiwan.
Article Synopsis
- A study tested the effectiveness of inhaled colistin in treating ventilator-associated pneumonia caused by resistant bacteria, using two types of nebulizers: a vibrating mesh nebulizer (VMN) and a jet nebulizer (JN).
- Patients receiving intravenous (IV) colistin inhalation were randomly assigned to either nebulizer type and compared to a control group receiving IV only over a period of 7 to 10 days, with a focus on clinical improvement.
- While VMN delivered a higher dose of colistin in lab tests, both nebulizers showed similar clinical outcomes in patients, showing significant benefits over the IV-only group.
Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis.
Antibiotics (Basel)
November 2024
Intensive Care Department, Palencia University Hospital Complex, 34004 Palencia, Spain.
Background: This study aims to assess the effectiveness and safety of cefiderocol in treating severe infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) in critically ill patients, particularly those in intensive care units (ICUs).
Methods: A meta-analysis of studies, including randomized clinical trials and observational studies in adult patients, was performed. Studies with at least 50% of critically ill patients were included.
Epidemiological study of hospital acquired acute kidney injury in critically ill and its effect on the survival.
Sci Rep
November 2024
Department of Biostatistics, St Johns Research Institute, Bangalore,, 560034, India.
In the intensive care unit (ICU), acute kidney injury (AKI) is the most common cause of morbidity and mortality. Hospital-acquired acute kidney injury (HAAKI) is AKI developing after 48 h. We aimed to study the development of AKI and its associated risk factors.
View Article and Find Full Text PDFMonte Carlo simulation for dosage optimization of the best available therapy for bloodstream infections secondary to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
J Glob Antimicrob Resist
December 2024
Department of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand; Pharmaceutical Initiative for Resistant Bacteria and Infectious Diseases Working Group [PIRBIG], Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand. Electronic address:
Objective: We aimed to use Monte Carlo simulation, based on pharmacokinetic/pharmacodynamic targets, to investigate and determine the optimal dosage of the available combination therapies for carbapenem-resistant Klebsiella pneumoniae (CRKP) in critically ill patients.
Methods: We collected CRKP clinical isolates from Phramongkutklao Hospital between October 2020 and June 2022. A molecular study of resistant genes was performed using polymerase chain reaction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!